Key result
Adding argatroban to antiplatelets increases excellent 90-day functional outcomes by ~36% in acute ischemic stroke.
Why the study?
Many acute ischemic stroke patients experience early neurological deterioration despite standard antiplatelet therapy, and the efficacy and safety of argatroban as an adjunct remain to be clarified.
Does argatroban combined with antiplatelet therapy improve functional outcomes in acute ischemic stroke patients?
Comparison
Argatroban plus single or dual antiplatelet therapy versus antiplatelets alone
Design
Systematic review and meta-analysis of RCTs and cohort studies
Follow-up
90 days
Authors
Loading...
Argatroban plus antiplatelets may improve functional outcomes and reduce END in AIS; supports adjunctive use with DAPT but leaves open need for large RCTs.
Meta-Analysis (n=10,108)
Does argatroban combined with antiplatelet therapy improve functional outcomes in acute ischemic stroke patients?
Odds Ratio: 1.36 (95% CI 1.05–1.76)
p-value: p=0.02
Argatroban combined with antiplatelet therapy improves functional recovery and reduces early neurological deterioration in acute ischemic stroke without increasing bleeding risks.
Moawad et al. (2025) conducted a meta-analysis in Acute ischemic stroke (n=10,108). Argatroban plus antiplatelet therapy vs. Antiplatelet therapy alone was evaluated on 90-day modified Rankin Score (mRS) of 0-2 (OR 1.36, 95% CI 1.05-1.76, p=0.02). Argatroban combined with antiplatelet therapy significantly increased the incidence of excellent functional outcomes (mRS 0-2) at 90 days compared to antiplatelets alone in patients with acute ischemic stroke (OR 1.36).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: